Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long‐term follow up
To evaluate the long‐term outcomes of rituximab in the treatment of pemphigus and the influence of disease duration and different dose of rituximab on the clinical response, 45 patients with refractory pemphigus treated with at least one cycle of two infusions of rituximab (375 mg/m2 per infusion we...
Gespeichert in:
| Veröffentlicht in: | Journal of dermatology 2017-06, Vol.44 (6), p.615-620 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 620 |
|---|---|
| container_issue | 6 |
| container_start_page | 615 |
| container_title | Journal of dermatology |
| container_volume | 44 |
| creator | Kim, Tae Hyung Choi, Yuri Lee, Sang Eun Lim, Jung Min Kim, Soo‐Chan |
| description | To evaluate the long‐term outcomes of rituximab in the treatment of pemphigus and the influence of disease duration and different dose of rituximab on the clinical response, 45 patients with refractory pemphigus treated with at least one cycle of two infusions of rituximab (375 mg/m2 per infusion weekly) were retrospectively studied. All patients were followed up for more than 2 years. All patients achieved complete or partial remission within 8 months of the first cycle. Thirty‐four (76%) patients relapsed at a median of 17 months. All patients who received additional cycles after relapse achieved new remissions. Early use of rituximab within 1 year of disease duration and high‐dose therapy induced better outcomes, although the results in early use were not statistically significant. Acute respiratory distress syndrome occurred in one patient. Rituximab is effective in treating pemphigus, but relapses are frequent during long‐term follow up, and additional cycles are beneficial in relapsed cases. Early and high‐dose rituximab therapy may be more effective. |
| doi_str_mv | 10.1111/1346-8138.13757 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1867547098</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1905590495</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4367-5891b231b8894a9eb3b7f0da89132ba46a14f6f176196b44a619866dd5cbef7f3</originalsourceid><addsrcrecordid>eNqFkTtvFDEUhS0EIptATYcs0dBMYo_fdKuQ8FAkGqgte8beeDUv_MiyDeIn8Bv5JXjZkIIGN1c--u7R1TkAvMDoHNd3gQnljcREnmMimHgEVg_KY7BCRLKmpUicgNOUtgi1imH0FJy0EktOmFyB7-t-W-7MlGEMuXwLo7EwR2fy6Krm5wgXNy63YVPSG7iG0eU4p8V1Odw5mHLp93D2kDK4mBzqSoImQwNTmDaDg11VXIS7kG_hME-bXz9-1v9YfYdh3sGyPANPvBmSe34_z8CX66vPl--bm0_vPlyub5qOEi4aJhW2LcFWSkWNcpZY4VFvqkxaayg3mHruseBYcUupqVNy3vess84LT87A66PvEuevxaWsx5A6NwxmcnNJusYhGBVIyYq--gfdziVO9TqNFWJMIapYpS6OVFfzSNF5vcQaXtxrjPShGn0oQh-K0H-qqRsv732LHV3_wP_togLsCOzC4Pb_89Mf314djX8D91GZ4g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1905590495</pqid></control><display><type>article</type><title>Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long‐term follow up</title><source>MEDLINE</source><source>Wiley Online Library</source><creator>Kim, Tae Hyung ; Choi, Yuri ; Lee, Sang Eun ; Lim, Jung Min ; Kim, Soo‐Chan</creator><creatorcontrib>Kim, Tae Hyung ; Choi, Yuri ; Lee, Sang Eun ; Lim, Jung Min ; Kim, Soo‐Chan</creatorcontrib><description>To evaluate the long‐term outcomes of rituximab in the treatment of pemphigus and the influence of disease duration and different dose of rituximab on the clinical response, 45 patients with refractory pemphigus treated with at least one cycle of two infusions of rituximab (375 mg/m2 per infusion weekly) were retrospectively studied. All patients were followed up for more than 2 years. All patients achieved complete or partial remission within 8 months of the first cycle. Thirty‐four (76%) patients relapsed at a median of 17 months. All patients who received additional cycles after relapse achieved new remissions. Early use of rituximab within 1 year of disease duration and high‐dose therapy induced better outcomes, although the results in early use were not statistically significant. Acute respiratory distress syndrome occurred in one patient. Rituximab is effective in treating pemphigus, but relapses are frequent during long‐term follow up, and additional cycles are beneficial in relapsed cases. Early and high‐dose rituximab therapy may be more effective.</description><identifier>ISSN: 0385-2407</identifier><identifier>EISSN: 1346-8138</identifier><identifier>DOI: 10.1111/1346-8138.13757</identifier><identifier>PMID: 28186358</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Autoimmune diseases ; early use ; Female ; Humans ; Immunologic Factors - administration & dosage ; Immunologic Factors - adverse effects ; Immunotherapy ; Male ; Middle Aged ; Monoclonal antibodies ; Patients ; Pemphigus ; Pemphigus - drug therapy ; Recurrence ; relapse ; Remission ; Respiratory distress syndrome ; retreatment ; Retrospective Studies ; Rituximab ; Rituximab - administration & dosage ; Rituximab - adverse effects ; Skin diseases ; Statistical analysis ; Treatment Outcome</subject><ispartof>Journal of dermatology, 2017-06, Vol.44 (6), p.615-620</ispartof><rights>2017 Japanese Dermatological Association</rights><rights>2017 Japanese Dermatological Association.</rights><rights>Copyright © 2017 Japanese Dermatological Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4367-5891b231b8894a9eb3b7f0da89132ba46a14f6f176196b44a619866dd5cbef7f3</citedby><cites>FETCH-LOGICAL-c4367-5891b231b8894a9eb3b7f0da89132ba46a14f6f176196b44a619866dd5cbef7f3</cites><orcidid>0000-0002-0223-5933</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2F1346-8138.13757$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2F1346-8138.13757$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28186358$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Tae Hyung</creatorcontrib><creatorcontrib>Choi, Yuri</creatorcontrib><creatorcontrib>Lee, Sang Eun</creatorcontrib><creatorcontrib>Lim, Jung Min</creatorcontrib><creatorcontrib>Kim, Soo‐Chan</creatorcontrib><title>Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long‐term follow up</title><title>Journal of dermatology</title><addtitle>J Dermatol</addtitle><description>To evaluate the long‐term outcomes of rituximab in the treatment of pemphigus and the influence of disease duration and different dose of rituximab on the clinical response, 45 patients with refractory pemphigus treated with at least one cycle of two infusions of rituximab (375 mg/m2 per infusion weekly) were retrospectively studied. All patients were followed up for more than 2 years. All patients achieved complete or partial remission within 8 months of the first cycle. Thirty‐four (76%) patients relapsed at a median of 17 months. All patients who received additional cycles after relapse achieved new remissions. Early use of rituximab within 1 year of disease duration and high‐dose therapy induced better outcomes, although the results in early use were not statistically significant. Acute respiratory distress syndrome occurred in one patient. Rituximab is effective in treating pemphigus, but relapses are frequent during long‐term follow up, and additional cycles are beneficial in relapsed cases. Early and high‐dose rituximab therapy may be more effective.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Autoimmune diseases</subject><subject>early use</subject><subject>Female</subject><subject>Humans</subject><subject>Immunologic Factors - administration & dosage</subject><subject>Immunologic Factors - adverse effects</subject><subject>Immunotherapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Pemphigus</subject><subject>Pemphigus - drug therapy</subject><subject>Recurrence</subject><subject>relapse</subject><subject>Remission</subject><subject>Respiratory distress syndrome</subject><subject>retreatment</subject><subject>Retrospective Studies</subject><subject>Rituximab</subject><subject>Rituximab - administration & dosage</subject><subject>Rituximab - adverse effects</subject><subject>Skin diseases</subject><subject>Statistical analysis</subject><subject>Treatment Outcome</subject><issn>0385-2407</issn><issn>1346-8138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkTtvFDEUhS0EIptATYcs0dBMYo_fdKuQ8FAkGqgte8beeDUv_MiyDeIn8Bv5JXjZkIIGN1c--u7R1TkAvMDoHNd3gQnljcREnmMimHgEVg_KY7BCRLKmpUicgNOUtgi1imH0FJy0EktOmFyB7-t-W-7MlGEMuXwLo7EwR2fy6Krm5wgXNy63YVPSG7iG0eU4p8V1Odw5mHLp93D2kDK4mBzqSoImQwNTmDaDg11VXIS7kG_hME-bXz9-1v9YfYdh3sGyPANPvBmSe34_z8CX66vPl--bm0_vPlyub5qOEi4aJhW2LcFWSkWNcpZY4VFvqkxaayg3mHruseBYcUupqVNy3vess84LT87A66PvEuevxaWsx5A6NwxmcnNJusYhGBVIyYq--gfdziVO9TqNFWJMIapYpS6OVFfzSNF5vcQaXtxrjPShGn0oQh-K0H-qqRsv732LHV3_wP_togLsCOzC4Pb_89Mf314djX8D91GZ4g</recordid><startdate>201706</startdate><enddate>201706</enddate><creator>Kim, Tae Hyung</creator><creator>Choi, Yuri</creator><creator>Lee, Sang Eun</creator><creator>Lim, Jung Min</creator><creator>Kim, Soo‐Chan</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0223-5933</orcidid></search><sort><creationdate>201706</creationdate><title>Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long‐term follow up</title><author>Kim, Tae Hyung ; Choi, Yuri ; Lee, Sang Eun ; Lim, Jung Min ; Kim, Soo‐Chan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4367-5891b231b8894a9eb3b7f0da89132ba46a14f6f176196b44a619866dd5cbef7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Autoimmune diseases</topic><topic>early use</topic><topic>Female</topic><topic>Humans</topic><topic>Immunologic Factors - administration & dosage</topic><topic>Immunologic Factors - adverse effects</topic><topic>Immunotherapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Pemphigus</topic><topic>Pemphigus - drug therapy</topic><topic>Recurrence</topic><topic>relapse</topic><topic>Remission</topic><topic>Respiratory distress syndrome</topic><topic>retreatment</topic><topic>Retrospective Studies</topic><topic>Rituximab</topic><topic>Rituximab - administration & dosage</topic><topic>Rituximab - adverse effects</topic><topic>Skin diseases</topic><topic>Statistical analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Tae Hyung</creatorcontrib><creatorcontrib>Choi, Yuri</creatorcontrib><creatorcontrib>Lee, Sang Eun</creatorcontrib><creatorcontrib>Lim, Jung Min</creatorcontrib><creatorcontrib>Kim, Soo‐Chan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Tae Hyung</au><au>Choi, Yuri</au><au>Lee, Sang Eun</au><au>Lim, Jung Min</au><au>Kim, Soo‐Chan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long‐term follow up</atitle><jtitle>Journal of dermatology</jtitle><addtitle>J Dermatol</addtitle><date>2017-06</date><risdate>2017</risdate><volume>44</volume><issue>6</issue><spage>615</spage><epage>620</epage><pages>615-620</pages><issn>0385-2407</issn><eissn>1346-8138</eissn><abstract>To evaluate the long‐term outcomes of rituximab in the treatment of pemphigus and the influence of disease duration and different dose of rituximab on the clinical response, 45 patients with refractory pemphigus treated with at least one cycle of two infusions of rituximab (375 mg/m2 per infusion weekly) were retrospectively studied. All patients were followed up for more than 2 years. All patients achieved complete or partial remission within 8 months of the first cycle. Thirty‐four (76%) patients relapsed at a median of 17 months. All patients who received additional cycles after relapse achieved new remissions. Early use of rituximab within 1 year of disease duration and high‐dose therapy induced better outcomes, although the results in early use were not statistically significant. Acute respiratory distress syndrome occurred in one patient. Rituximab is effective in treating pemphigus, but relapses are frequent during long‐term follow up, and additional cycles are beneficial in relapsed cases. Early and high‐dose rituximab therapy may be more effective.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28186358</pmid><doi>10.1111/1346-8138.13757</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-0223-5933</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0385-2407 |
| ispartof | Journal of dermatology, 2017-06, Vol.44 (6), p.615-620 |
| issn | 0385-2407 1346-8138 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1867547098 |
| source | MEDLINE; Wiley Online Library |
| subjects | Adult Aged Aged, 80 and over Autoimmune diseases early use Female Humans Immunologic Factors - administration & dosage Immunologic Factors - adverse effects Immunotherapy Male Middle Aged Monoclonal antibodies Patients Pemphigus Pemphigus - drug therapy Recurrence relapse Remission Respiratory distress syndrome retreatment Retrospective Studies Rituximab Rituximab - administration & dosage Rituximab - adverse effects Skin diseases Statistical analysis Treatment Outcome |
| title | Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long‐term follow up |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T20%3A11%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjuvant%20rituximab%20treatment%20for%20pemphigus:%20A%20retrospective%20study%20of%2045%20patients%20at%20a%20single%20center%20with%20long%E2%80%90term%20follow%20up&rft.jtitle=Journal%20of%20dermatology&rft.au=Kim,%20Tae%20Hyung&rft.date=2017-06&rft.volume=44&rft.issue=6&rft.spage=615&rft.epage=620&rft.pages=615-620&rft.issn=0385-2407&rft.eissn=1346-8138&rft_id=info:doi/10.1111/1346-8138.13757&rft_dat=%3Cproquest_cross%3E1905590495%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1905590495&rft_id=info:pmid/28186358&rfr_iscdi=true |